Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.
Jing-Yi Chern, MD, ScM, a gynecologic oncologist at Moffitt Cancer Center, discusses future research directions in the treatment of patients with ovarian cancer.
Currently, at Moffit Cancer Center, there are efforts underway to identify patients early on and ensure that they receive a maintenance therapy regimen, if appropriate, Chern says. Pathways have been developed to identifypatients and test them early in their treatment to ensure they are ready for maintenance therapy, Chern notes. Additionally, these pathways have allowed healthcare providers to identify other mutations that could allow patients easier access to clinical trials, according to Chern.
Clinical trials for this patient population include those evaluating PARP inhibitors, antibody-drug conjugates, and immunotherapy, and are ongoing at Moffitt Cancer Center, as well as at other institutions, Chern explains. Through this research, providers are able to find opportunities for patients to receive treatments that they otherwise could not receive, Chern concludes.